Who owns Headway? Ownership structure explained (2026)

Headway is a private healthcare marketplace that helps patients find therapists and psychiatrists who accept insurance. It also gives providers tools for credentialing, scheduling, billing, and claims. That position between patients, clinicians, and health plans makes its ownership relevant to how the platform expands and handles sensitive information.

The company has raised capital from several prominent venture firms, but it does not publish founder stakes, investor percentages, or a complete board roster. Its ownership is therefore best understood through announced funding rounds, confirmed board appointments, and the control rights that normally accompany preferred shares.

Headway was founded in New York City in 2019 by Andrew Adams, Jake Sussman, Daniel Ross, and Kevin Chan. Adams has said the idea grew from his own difficulty finding a therapist who accepted his insurance. He remains chief executive officer.

Headway operates a two-sided network. Patients search for in-network mental health professionals, while clinicians use the platform to join insurer networks and manage administrative work. The company earns revenue through its commercial relationships with health plans rather than charging patients a marketplace subscription. This model connects Headway to the economics of the medical billing industry, where eligibility checks and claims accuracy directly affect payment.

Headway has not published annual revenue. Its most recent confirmed valuation was $2.3 billion in July 2024. Later product and expansion announcements did not include a new priced financing.

Headway is an independent, privately held company. No public corporation owns it, and there is no evidence that one investor has disclosed majority control. Common stock is likely held by founders and employees, while venture investors hold preferred shares with negotiated economic and governance rights. The exact percentages are not public.

The four co-founders received the original common equity, but Headway has never disclosed how that equity was divided or how much each founder retains after multiple funding rounds. Andrew Adams is the only founder still identified publicly as an operating executive. His CEO role gives him substantial day-to-day influence, but it does not prove voting control.

Successive venture rounds diluted the founders' percentage ownership. The degree of dilution cannot be calculated from the announced amounts and valuations alone because option pools, secondary sales, liquidation preferences, and the precise share counts are private.

The announced Series A through Series D rounds total $321 million. Some databases include an earlier seed investment and report a slightly higher lifetime total. Because Headway did not separately publish the seed amount, “more than $320 million” is the most defensible public figure.

Spark Capital led both the Series C and Series D. Partner Will Reed joined Headway's board with the Series C, giving Spark a confirmed governance role as well as a financial stake.

Thrive Capital co-led the Series A (with GV) and participated in later rounds. Its early position means it likely holds one of the more significant institutional stakes, although the percentage is undisclosed.

Andreessen Horowitz led the Series B, which valued Headway at $750 million. The firm has also held a board relationship. Its stake was diluted by later rounds, but it remains a named backer.

Accel, GV, and Forerunner Ventures also appear in Headway's announced financing history. Accel and GV backed the company early, while Forerunner joined in the Series D. These firms add healthcare, marketplace, and consumer-growth expertise without creating a publicly identified controlling owner.

Headway has not filed publicly for an initial public offering or announced a formal listing timetable. Its 2024 valuation and national expansion make a future IPO possible, but that is not the same as an active process. Until a filing or acquisition occurs, ownership remains divided among founders, employees, and private investors. A useful contrast is the public-company ownership of Hims & Hers, a consumer-health platform that already made the jump Headway has not.

Andrew Adams is co-founder and CEO. He leads strategy, insurer relationships, expansion, and fundraising. Headway has not published a complete current executive roster or detailed founder responsibilities, so claims about continuing operating authority for the other co-founders should be treated cautiously.

Will Reed of Spark Capital is a confirmed director. Investor representatives have joined the board at earlier rounds, but Headway does not maintain a public governance page with a current list of every director. It is therefore reasonable to infer that major preferred shareholders have board or observer rights, but not to assign seats that the company has not recently confirmed.

This differs from the unusually concentrated founder control in Epic Systems' ownership model. Headway's control is shared across management and institutional investors, subject to private shareholder agreements.

Headway has faced proposed class-action claims alleging that website analytics tools transmitted information about users' searches for mental health providers. The company has disputed liability. In 2024, a federal court allowed material privacy claims to continue, and as of 2026 the allegations remain unresolved rather than proven. The case highlights the sensitivity of behavioral-health search data.

The platform handles protected health information and increasingly uses automation in administrative workflows. That creates obligations under HIPAA, state privacy laws, cybersecurity rules, and insurer contracts. Headway must separate permitted healthcare operations from uses that could require additional consent. Its risk controls can be assessed using a structured risk register template.

Headway gives patients cost estimates based on insurer information, but final responsibility depends on the health plan's adjudication. Its terms warn that estimates can change. Providers also depend on Headway's credentialing and claims processes. Errors, denials, or clawbacks can therefore create disputes even when the underlying clinical care is appropriate.

Headway's growth depends on contracts with major insurers. A payer can affect reimbursement rates, network access, and claim rules across many providers at once. That concentration gives health plans meaningful commercial leverage even though they do not own Headway.

Headway's venture ownership has financed rapid network expansion. It has also set expectations for growth and a future liquidity event. A $2.3 billion private valuation must eventually be supported by public-market demand, an acquisition, or sustained cash generation. The business valuation calculator illustrates why valuation and ownership percentage are separate questions.

Founder-led management can keep the product focused on reducing administrative friction. Investor board rights, however, mean strategic decisions are not made by the CEO alone. Preferred shareholders may have approval rights over a sale, a new financing, or changes to the capital structure.

For clinicians, ownership matters because investor-backed expansion can bring more payer contracts and operational support. It can also increase pressure to standardize workflows, control claim quality, and improve margins. Providers should understand which decisions remain theirs and which are governed by platform or insurer rules.

For patients, the main issue is trust. Headway's value depends on making care easier to access without compromising privacy or creating unexpected bills. Its owners benefit when more care flows through the platform, while users need clear safeguards around data and payment. That same tension between owner incentives and user trust runs through how GoodRx is owned.

Andrew Adams is Headway's co-founder and CEO. He has led the company since its founding in 2019.

No. Headway is a privately held company. It has not filed publicly for an IPO and has no public stock ticker.

Headway was founded by Andrew Adams, Jake Sussman, Daniel Ross, and Kevin Chan. The company launched in New York City in 2019.

Headway does not disclose shareholder percentages. Its most prominent institutional backers include Spark Capital, Thrive Capital, Andreessen Horowitz, Accel, GV, and Forerunner Ventures. Founders and employees also hold common equity.

Headway's publicly announced Series A through Series D rounds total $321 million. Including early seed financing, the lifetime total is higher, but the company has not published enough detail to state an exact amount with confidence.

The latest confirmed valuation is $2.3 billion from the July 2024 Series D. There is no later publicly announced priced round.